Theralizumab
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS) . Theralizumab can be used for the research of rheumatoid arthritis[1][2].
Product Specifications
CAS Number
906068-56-2
Product Name Alternative
TGN1412; TAB08
UNSPSC
12352203
Target
CD28
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/theralizumab.html
Purity
99.46
Solubility
H2O
Smiles
[Theralizumab]
Molecular Weight
(145.62 kDa)
References & Citations
[1]Thomas Hünig. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. FEBS J. 2016 Sep;283 (18) :3325-34.|[2]Dmitry Tyrsin, et al. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. Jul-Aug 2016;34 (4 Suppl 98) :45-8.|[3]Weißmüller S, et al. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One. 2016 Mar 9;11 (3) :e0149093.|[4]Hussain K, et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood. 2015 Jan 1;125 (1) :102-10.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
KN204619RB 1 Kit
Syndecan 4 (SDC4) Human Gene Knockout Kit (CRISPR)
Sign In for Pricing
View Details 
